Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resomelagon in early RA
NCT05516979Phase 2Completed
- Sponsor
- SynAct Pharma AB
- Start
- Sep 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing 100 mg AP1189 with Placebo (2 arms). Primary endpoints: Adverse Events at 12 weeks and ACR20 Response at 12 weeks. Started Sep 2022; status: completed.
02
Drugs
resomelagon
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05516979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516979.